Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STALORAL Birch 300 IR in children and adolescents with birch pollen-induced allergic rhinoconjunctivitis
2022-002012-23Phase 3Active
- Sponsor
- Stallergenes Greer
- Start
- Jul 2022
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) and asthma comparing STALORAL Birch 300 IR with Placebo (2 arms). Primary endpoint: Average ARC Total Combined Score over BPS2. Started Jul 2022; status: active.
02
Drugs
allergenic extract of birch
03
Conditions
allergic rhinoconjunctivitis (ARC)asthma
Beyond the preview
Go deeper on 2022-002012-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002012-23.